Silyl Monomers for Multimeric Protein Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug design and therapies fail to effectively modulate protein-protein interactions, particularly in cancer, due to limitations in targeting multiple protein domains simultaneously and achieving oral bioavailability.
Innovation Solution
Development of monomers capable of forming biologically useful multimers in aqueous media, comprising a ligand moiety, linker element, and connector element, which can bind to multiple protein domains simultaneously, enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large covalently linked compounds are assembled to disrupt protein-protein interactions, then binding affinity to multiple protein domains is improved, but molecular weight becomes too large for oral administration and cellular permeation
Solution Approach 1:
The patent divides the therapeutic agent into separate monomeric units that can be administered individually and then assemble into multimers within the body. Each monomer contains a ligand moiety and a connector element with silanol groups that enable self-assembly. This segmentation allows the individual components to have suitable molecular weight for oral administration while the assembled multimer achieves the desired binding affinity to multiple protein domains.
Solution Approach 2:
The patent employs a hierarchical structure where monomeric units (containing ligand moieties and connector elements) nest together through siloxane bond formation to create multimeric assemblies. The monomers act as building blocks that contain the essential functional elements, and they nest together to form the complete therapeutic multimer that can simultaneously engage multiple protein domains.
2Reliability
If antibodies and biological therapeutic agents are used to distinguish among closely related protein surfaces, then specificity is improved, but high molecular weight prevents oral administration and uptake
Solution Approach 1:
The patent segments the therapeutic function into separate monomeric units that can be orally administered. Each monomer contains a ligand moiety capable of specific binding to target protein domains, and a connector element with silanol groups. The segmented design reduces molecular weight to enable oral administration while maintaining specificity through the ligand moieties.
Solution Approach 2:
The patent changes the molecular weight parameter by using small monomeric building blocks instead of large antibody molecules. The monomers have molecular weights suitable for oral absorption, and their specific binding capability is maintained through carefully designed ligand moieties. The multimeric assembly achieves enhanced specificity through cooperative binding to multiple domains.
3Ease of operation
If orally active pharmaceuticals are used to achieve sufficient cellular permeation, then bioavailability is improved, but molecular size is too small to disrupt protein-protein surface interactions
Solution Approach 1:
The patent uses segmented monomeric units that can be orally administered and cellularly permeated due to their small size. Each monomer contains a ligand moiety with binding capability and a connector element. The segmentation allows individual monomers to pass through cell membranes while the assembled multimer achieves sufficient size to disrupt protein-protein interactions through multivalent binding.
Solution Approach 2:
The patent transitions from single-dimensional small molecule binding to multi-dimensional multimeric assembly. The monomers have the dimensionality required for cellular permeation, but when assembled into multimers, they gain extended spatial reach through the connector elements, enabling simultaneous engagement with multiple protein domains that a single small molecule cannot access.
4Adaptability or versatility
If monomers are designed to form multimers in aqueous media, then ability to modulate multiple protein domains simultaneously is improved, but complexity of multimer assembly increases
Solution Approach 1:
The patent employs self-service assembly where monomeric units automatically assemble into multimers through spontaneous siloxane bond formation between silanol groups. The connector elements are designed to self-assemble without external intervention, using the natural reactivity of silanol groups in aqueous media. This self-assembly mechanism reduces the complexity of manufacturing and formulation while enabling versatile multimeric structures that can modulate multiple protein domains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimeric approach allows for simultaneous modulation of multiple protein domains, potentially improving therapeutic outcomes by increasing binding affinity and bioavailability, thereby addressing the limitations of existing therapies.
Implementation Method 1
The monomers may be capable of joining together to form a multimer in vivo. The multimeric compounds described herein may be formed, at least in part, by the joining together of two or more monomers
Data Source
AI summary
Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.